RG

Redmile Group Portfolio holdings

AUM $1.49B Turnover 10.26%
1-Year Est. Return 208.7%
This Fund
S&P 500
This Quarter Est. Return
+7.72%
1 Year Est. Return
+208.7%
3 Year Est. Return
+777.5%
5 Year Est. Return
+1,114.43%
10 Year Est. Return
+23,630.52%
AUM
$866M
AUM Growth
+$41.2M
Cap. Flow
-$23.2M
Cap. Flow %
-2.68%
Top 10 Hldgs %
41.18%
Holding
70
New
22
Increased
15
Reduced
16
Closed
15
Avg Time Held Equity + Options
0.5 years
Top 10 Avg Time Held Equity + Options
0.3 years
Top 20 Avg Time Held Equity + Options
0.4 years
Avg Time Held Equity only
0.5 years
Top 10 Avg Time Held Equity only
0.3 years
Top 20 Avg Time Held Equity only
0.4 years

Top Buys

Rank Stock Value
1
CELG
Celgene Corp
CELG
+$33.3M
2
MCK icon
McKesson
MCK
+$31.1M
3
ADVM icon
Adverum Biotechnologies
ADVM
+$20.8M
4
CBST
CUBIST PHARMACEUTICALS INC
CBST
+$18.6M
5
MNK
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
+$18.1M

Top Sells

Rank Stock Value
1
MDT icon
Medtronic
MDT
+$37.6M
2
AGN
Allergan Inc
AGN
+$28.8M
3
ZBH icon
Zimmer Biomet
ZBH
+$26.6M
4
UHS icon
Universal Health Services
UHS
+$26.1M
5
A icon
Agilent Technologies
A
+$19.9M

Sector Composition

Rank Sector Weight
1 Healthcare 75.81%
2 Miscellaneous 18.86%
3 Technology 2.52%
4 Communication Services 1.66%
5 Industrials 0.66%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
INSM icon
26
Insmed
INSM
$21.4B
$14.2M 1.64%
+1,090,624
New +$16.4M
2014 Q3
0 quarters
ITCI icon
27
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$13.8M 1.59%
1,003,496
+24,050
+2% +$361K
2014 Q1
2 quarters
LAB icon
28
Standard BioTools
LAB
$248M
$13.7M 1.58%
559,622
+167,082
+43% +$4.7M
2014 Q2
1 quarter
WCG
29
DELISTED
Wellcare Health Plans, Inc.
WCG
$13.6M 1.57%
+225,033
New +$14.9M
2014 Q3
0 quarters
UHS icon
30
Universal Health Services
UHS
$11B
$12.9M 1.49%
123,792
-245,811
-67% -$26.1M
2014 Q2
1 quarter
BMRN icon
31
BioMarin Pharmaceuticals
BMRN
$10.7B
$12.8M 1.48%
177,079
-291,021
-62% -$19.1M
2014 Q2
1 quarter
PBYI icon
32
Puma Biotechnology
PBYI
$527M
$12.2M 1.41%
+51,025
New +$10.5M
2014 Q3
0 quarters
PRQR icon
33
ProQR Therapeutics
PRQR
$207M
$12.1M 1.39%
+765,232
New +$12.3M
2014 Q3
0 quarters
ARAY icon
34
Accuray
ARAY
$20.9M
$12M 1.39%
1,653,128
-213,132
-11% -$1.73M
2013 Q3
4 quarters
CIVI icon
35
DELISTED
Civitas Solutions, Inc.
CIVI
$9.67M 1.12%
+619,236
New +$10.1M
2014 Q3
0 quarters
KYTH
36
DELISTED
KYTHERA BIOPHARMACEUTICALS, INC COM
KYTH
$9.22M 1.07%
281,479
-278,877
-50% -$9.82M
2013 Q2
5 quarters
ALGN icon
37
Align Technology
ALGN
$10.3B
$8.93M 1.03%
172,772
-2,680
-2% -$146K
2014 Q1
2 quarters
CYBX
38
DELISTED
CYBERONICS INC
CYBX
$8.85M 1.02%
+172,900
New +$9.97M
2014 Q3
0 quarters
CSII
39
DELISTED
Cardiovascular Systems, Inc.
CSII
$8.75M 1.01%
370,208
-123,137
-25% -$3.5M
2014 Q1
2 quarters
FLXN icon
40
DELISTED
Flexion Therapeutics, Inc.
FLXN
$8.51M 0.98%
465,933
-38,150
-8% -$552K
2014 Q1
2 quarters
LOXO
41
DELISTED
Loxo Oncology, Inc
LOXO
$7.09M 0.82%
+540,300
New +$7.01M
2014 Q3
0 quarters
AKAO
42
DELISTED
Achaogen Inc
AKAO
$6.9M 0.8%
770,422
+121,543
+19% +$1.24M
2014 Q1
2 quarters
ELDN icon
43
Eledon Pharmaceuticals
ELDN
$183M
$6.27M 0.72%
+2,558
New +$7.27M
2014 Q3
0 quarters
HMSY
44
DELISTED
HMS Holdings Corp.
HMSY
$5.72M 0.66%
303,571
-262,022
-46% -$5.3M
2014 Q2
1 quarter
SGEN
45
DELISTED
Seagen Inc. Common Stock
SGEN
$4.77M 0.55%
+128,230
New +$5.04M
2014 Q3
0 quarters
CLVS
46
CALL
DELISTED
Clovis Oncology, Inc.
CLVS
$4.54M 0.52%
+100,000
New +$4.18M
2014 Q3
0 quarters
EHTH icon
47
eHealth
EHTH
$19.5M
$4.29M 0.5%
+177,788
New +$4.85M
2014 Q3
0 quarters
AGIO icon
48
Agios Pharmaceuticals
AGIO
$1.85B
$3.02M 0.35%
+49,200
New +$2.12M
2014 Q3
0 quarters
PRTA icon
49
Prothena Corp
PRTA
$430M
$2.79M 0.32%
125,973
-244,547
-66% -$5.18M
2013 Q4
3 quarters
ICPT
50
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$524K 0.06%
2,212
+1,150
+108% +$293K
2013 Q4
3 quarters
1
2
3

Similar funds

FCM
Fairholme Capital Management South Miami, Florida $1.49B AUM 28.35% 1-Year Est. Return
MM
Main Management San Francisco, California $1.49B AUM 22.28% 1-Year Est. Return
WA
WBH Advisory Baltimore, Maryland $1.49B AUM 20.41% 1-Year Est. Return
ACB
Aristotle Capital Boston Boston, Massachusetts $1.49B AUM 32.81% 1-Year Est. Return
LCS
Levin Capital Strategies New York $1.49B AUM 30.44% 1-Year Est. Return
GAM
Gemmer Asset Management Walnut Creek, California $1.49B AUM 42.66% 1-Year Est. Return
MFWP
Mosaic Family Wealth Partners St. Louis, Missouri $1.49B AUM 26.43% 1-Year Est. Return
PMG
ProVise Management Group Clearwater, Florida $1.49B AUM 21.79% 1-Year Est. Return

Redmile Group's Q3 2014 Portfolio in Review

As of Q3 2014, Redmile Group held 70 positions worth $866M, up 5% from $825M the previous quarter. Its ten largest holdings account for 41% of the portfolio.

Redmile Group's Q3 2014 filing shows 22 new, 15 increased, 16 reduced and 15 closed positions. Its largest new stake was Celgene Corp: 369,400 shares worth $35M. The largest sale was Medtronic, an estimated $37.6M.

By sector, the portfolio is most concentrated in Healthcare at 76% of assets, down from 83% a quarter earlier, followed by Miscellaneous and Technology.

  • Redmile Group's largest Q3 2014 buy was Celgene Corp: 369,400 shares worth $35M.
  • Redmile Group added most to Rite Aid Corporation in Q3 2014, an estimated $18M increase.
  • Redmile Group's biggest Q3 2014 reduction was Universal Health Services, cutting an estimated $26.1M.
  • Redmile Group fully exited Medtronic in Q3 2014, selling an estimated $37.6M.
  • Redmile Group's ten largest holdings make up 41% of its $866M portfolio in Q3 2014.
  • Redmile Group opened 22 new positions and closed 15 in Q3 2014.
  • Redmile Group's portfolio value rose 5% quarter-over-quarter to $866M.

Based on Redmile Group's 13F filing for Q3 2014, filed 14 Nov 2014.